Compare LESL & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LESL | CUE |
|---|---|---|
| Founded | 1963 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7M | 17.6M |
| IPO Year | 2020 | 2017 |
| Metric | LESL | CUE |
|---|---|---|
| Price | $1.47 | $31.74 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | $2.54 | ★ $120.00 |
| AVG Volume (30 Days) | 133.1K | ★ 7.6M |
| Earning Date | 05-18-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.11 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,241,915,000.00 | $27,466,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.62 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 195.75 |
| 52 Week Low | $0.27 | $0.17 |
| 52 Week High | $6.92 | $41.42 |
| Indicator | LESL | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 46.89 | 73.24 |
| Support Level | $0.90 | $0.40 |
| Resistance Level | $1.60 | N/A |
| Average True Range (ATR) | 0.27 | 5.74 |
| MACD | -0.06 | 2.02 |
| Stochastic Oscillator | 12.38 | 74.86 |
Leslies Inc is a direct-to-consumer pool and spa care brand offering a comprehensive assortment of products, including chemicals, equipment and parts, cleaning and maintenance equipment, and safety, recreational, and fitness-related products. The company serves residential pool, residential spa, professional pool, and commercial pool consumers and markets its products through over 1,000 company-operated locations in 39 states and e-commerce websites, operating only in the United States. It operates mainly in the pool and spa aftermarket industry and offers regularly purchased, non-discretionary maintenance items, along with installation and repair services for pool and spa equipment.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.